Blueprint Medicines 주식 (NASDAQ: BPMC)

에 대한 최신 뉴스 Blueprint Medicines (NASDAQ:BPMC) 주식

Blueprint Medicines

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines Corp

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/16/24</td>
<td>$29.00</td>
<td>$46.5K</td>
<td>31.3K</td>
<td>38.7K</td>
</tr>
<tr>
<td>IBRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$4.00</td>
<td>$97.6K</td>
<td>250</td>
<td>10.0K</td>
</tr>
<tr>
<td>VRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$25.00</td>
<td>$43.7K</td>
<td>1.4K</td>
<td>1.1K</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$17.50</td>
<td>$38.0K</td>
<td>3.2K</td>
<td>954</td>
</tr>
<tr>
<td>NBIX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$150.00</td>
<td>$45.6K</td>
<td>782</td>
<td>321</td>
</tr>
<tr>
<td>EW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$67.50</td>
<td>$29.9K</td>
<td>768</td>
<td>104</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/23/24</td>
<td>$126.00</td>
<td>$56.4K</td>
<td>8</td>
<td>86</td>
</tr>
<tr>
<td>BPMC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$105.00</td>
<td>$42.3K</td>
<td>417</td>
<td>58</td>
</tr>
<tr>
<td>EXAS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$50.00</td>
<td>$67.5K</td>
<td>488</td>
<td>16</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option trade with neutral sentiment. It expires in 3 day(s) on August 16, 2024. Parties traded 1500 contract(s) at a $29.00 strike. The total cost received by the writing party (or parties) was $46.5K, with a price of $31.0 per contract. There were 31318 open contracts at this strike prior to today, and today 38747 contract(s) were bought and sold. 
• For IBRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>), we notice a call option trade that happens to be bearish, expiring in 66 day(s) on October 18, 2024. This event was a transfer of 2169 contract(s) at a $4.00 strike. The total cost received by the writing party (or parties) was $97.6K, with a price of $45.0 per contract. There were 250 open contracts at this strike prior to today, and today 10038 contract(s) were bought and sold. 
• Regarding VRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>), we observe a call option sweep with bearish sentiment. It expires in 3 day(s) on August 16, 2024. Parties traded 199 contract(s) at a $25.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $43.7K, with a price of $220.0 per contract. There were 1424 open contracts at this strike prior to today, and today 1129 contract(s) were bought and sold. 
• Regarding SAVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>), we observe a put option sweep with bearish sentiment. It expires in 157 day(s) on January 17, 2025. Parties traded 40 contract(s) at a $17.50 strike. This particular put needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $38.0K, with a price of $951.0 per contract. There were 3205 open contracts at this strike prior to today, and today 954 contract(s) were bought and sold. 
• Regarding NBIX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>), we observe a call option trade with bullish sentiment. It expires in 38 day(s) on September 20, 2024. Parties traded 30 contract(s) at a $150.00 strike. The total cost received by the writing party (or parties) was $45.6K, with a price of $1520.0 per contract. There were 782 open contracts at this strike prior to today, and today 321 contract(s) were bought and sold. 
• Regarding EW (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), we observe a call option trade with bullish sentiment. It expires in 94 day(s) on November 15, 2024. Parties traded 65 contract(s) at a $67.50 strike. The total cost received by the writing party (or parties) was $29.9K, with a price of $460.0 per contract. There were 768 open contracts at this strike prior to today, and today 104 contract(s) were bought and sold. 
• Regarding MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we observe a put option trade with bearish sentiment. It expires in 10 day(s) on August 23, 2024. Parties traded 47 contract(s) at a $126.00 strike. The total cost received by the writing party (or parties) was $56.4K, with a price of $1202.0 per contract. There were 8 open contracts at this strike prior to today, and today 86 contract(s) were bought and sold. 
• Regarding BPMC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>), we observe a put option trade with bearish sentiment. It expires in 66 day(s) on October 18, 2024. Parties traded 29 contract(s) at a $105.00 strike. The total cost received by the writing party (or parties) was $42.3K, with a price of $1460.0 per contract. There were 417 open contracts at this strike prior to today, and today 58 contract(s) were bought and sold. 
• For EXAS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), we notice a call option trade that happens to be neutral, expiring in 157 day(s) on January 17, 2025. This event was a transfer of 50 contract(s) at a $50.00 strike. The total cost received by the writing party (or parties) was $67.5K, with a price of $1350.0 per contract. There were 488 open contracts at this strike prior to today, and today 16 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

BPMC

EXAS

IBRX

NBIX

SAVA

VRNA

9 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$35.00</td>
<td>$127.1K</td>
<td>48.0K</td>
<td>3.3K</td>
</tr>
<tr>
<td>NTRA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$105.00</td>
<td>$36.6K</td>
<td>113</td>
<td>1.7K</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$450.00</td>
<td>$30.7K</td>
<td>575</td>
<td>519</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$57.50</td>
<td>$28.0K</td>
<td>3.2K</td>
<td>322</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/16/24</td>
<td>$85.00</td>
<td>$29.7K</td>
<td>945</td>
<td>153</td>
</tr>
<tr>
<td>QDEL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$60.00</td>
<td>$29.0K</td>
<td>0</td>
<td>146</td>
</tr>
<tr>
<td>HROW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$12.00</td>
<td>$66.0K</td>
<td>339</td>
<td>100</td>
</tr>
<tr>
<td>BPMC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$95.00</td>
<td>$30.6K</td>
<td>1</td>
<td>80</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$900.00</td>
<td>$76.0K</td>
<td>308</td>
<td>61</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$120.00</td>
<td>$75.1K</td>
<td>83</td>
<td>55</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option trade with bullish sentiment. It expires in 162 day(s) on January 17, 2025. Parties traded 3100 contract(s) at a $35.00 strike. The total cost received by the writing party (or parties) was $127.1K, with a price of $41.0 per contract. There were 48092 open contracts at this strike prior to today, and today 3303 contract(s) were bought and sold. 
• For NTRA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), we notice a call option sweep that happens to be bearish, expiring in 8 day(s) on August 16, 2024. This event was a transfer of 39 contract(s) at a $105.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $36.6K, with a price of $940.0 per contract. There were 113 open contracts at this strike prior to today, and today 1738 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option sweep that happens to be bullish, expiring in 134 day(s) on December 20, 2024. This event was a transfer of 58 contract(s) at a $450.00 strike. This particular put needed to be split into 20 different trades to become filled. The total cost received by the writing party (or parties) was $30.7K, with a price of $530.0 per contract. There were 575 open contracts at this strike prior to today, and today 519 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option trade with bearish sentiment. It expires in 43 day(s) on September 20, 2024. Parties traded 100 contract(s) at a $57.50 strike. The total cost received by the writing party (or parties) was $28.0K, with a price of $280.0 per contract. There were 3203 open contracts at this strike prior to today, and today 322 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a put option sweep with neutral sentiment. It expires in 8 day(s) on August 16, 2024. Parties traded 100 contract(s) at a $85.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $29.7K, with a price of $298.0 per contract. There were 945 open contracts at this strike prior to today, and today 153 contract(s) were bought and sold. 
• For QDEL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>), we notice a call option sweep that happens to be bullish, expiring in 225 day(s) on March 21, 2025. This event was a transfer of 121 contract(s) at a $60.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $29.0K, with a price of $240.0 per contract. There were 0 open contracts at this strike prior to today, and today 146 contract(s) were bought and sold. 
• For HROW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>), we notice a call option trade that happens to be bearish, expiring in 71 day(s) on October 18, 2024. This event was a transfer of 30 contract(s) at a $12.00 strike. The total cost received by the writing party (or parties) was $66.0K, with a price of $2200.0 per contract. There were 339 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
• For BPMC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>), we notice a call option trade that happens to be bearish, expiring in 162 day(s) on January 17, 2025. This event was a transfer of 30 contract(s) at a $95.00 strike. The total cost received by the writing party (or parties) was $30.6K, with a price of $1020.0 per contract. There were 1 open contracts at this strike prior to today, and today 80 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be bullish, expiring in 99 day(s) on November 15, 2024. This event was a transfer of 20 contract(s) at a $900.00 strike. The total cost received by the writing party (or parties) was $76.0K, with a price of $3800.0 per contract. There were 308 open contracts at this strike prior to today, and today 61 contract(s) were bought and sold. 
• Regarding DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we observe a call option sweep with bearish sentiment. It expires in 134 day(s) on December 20, 2024. Parties traded 5 contract(s) at a $120.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $75.1K, with a price of $15020.0 per contract. There were 83 open contracts at this strike prior to today, and today 55 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HROW

MRNA

NTRA

QDEL

10 Health Care Stocks Whale Activity In Today's Session

Needham analyst Ami Fadia maintains Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Buy and raises the price target from $130 to $133.

News

Price Target

Analyst Ratings

Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $133

Guggenheim analyst Michael Schmitz maintains Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Buy and raises the price target from $130 to $138.

Guggenheim Maintains Buy on Blueprint Medicines, Raises Price Target to $138

Baird analyst Joel Beatty maintains Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Outperform and raises the price target from $112 to $127.

Baird Maintains Outperform on Blueprint Medicines, Raises Price Target to $127

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Buy and maintains $130 price target.

Reiteration

Needham Reiterates Buy on Blueprint Medicines, Maintains $130 Price Target

Guidance

Blueprint Medicines Continues To Expect That Full-year Operating Expenses And Cash Burn Will Decline In 2024 As Compared To 2023

Blueprint Medicines Corp Raised 2024 Global AYVAKIT Net Product Revenue Outlook To $435M-$450M (From $390M-$410M)

Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(1.30) by 38.46 percent. The company reported quarterly sales of $138.157 million which beat the analyst consensus estimate of $103.575 million by 33.39 percent. This is a 139.98 percent increase over sales of $57.570 million the same period last year.

Earnings

Earnings Beats

Blueprint Medicines Q2 2024 GAAP EPS $(0.80) Beats $(1.30) Estimate, Sales $138.157M Beat $103.575M Estimate

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/09/24</td>
<td>$31.00</td>
<td>$33.0K</td>
<td>3.6K</td>
<td>5.9K</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/02/24</td>
<td>$50.00</td>
<td>$95.0K</td>
<td>1.7K</td>
<td>4.7K</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$16.00</td>
<td>$26.4K</td>
<td>34.6K</td>
<td>3.1K</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$125.00</td>
<td>$35.0K</td>
<td>3.8K</td>
<td>1.5K</td>
</tr>
<tr>
<td>GEHC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/09/24</td>
<td>$81.00</td>
<td>$28.3K</td>
<td>47</td>
<td>748</td>
</tr>
<tr>
<td>BPMC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$120.00</td>
<td>$44.2K</td>
<td>2.3K</td>
<td>227</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$48.00</td>
<td>$29.5K</td>
<td>377</td>
<td>210</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$750.00</td>
<td>$26.5K</td>
<td>1.0K</td>
<td>182</td>
</tr>
<tr>
<td>COR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$230.00</td>
<td>$27.4K</td>
<td>176</td>
<td>158</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$350.00</td>
<td>$36.3K</td>
<td>769</td>
<td>147</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option sweep with bearish sentiment. It expires in 10 day(s) on August 9, 2024. Parties traded 508 contract(s) at a $31.00 strike. This particular call needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $33.0K, with a price of $65.0 per contract. There were 3660 open contracts at this strike prior to today, and today 5915 contract(s) were bought and sold. 
• For BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we notice a call option sweep that happens to be bullish, expiring in 3 day(s) on August 2, 2024. This event was a transfer of 3395 contract(s) at a $50.00 strike. This particular call needed to be split into 63 different trades to become filled. The total cost received by the writing party (or parties) was $95.0K, with a price of $28.0 per contract. There were 1798 open contracts at this strike prior to today, and today 4759 contract(s) were bought and sold. 
• Regarding TEVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), we observe a call option trade with bullish sentiment. It expires in 52 day(s) on September 20, 2024. Parties traded 200 contract(s) at a $16.00 strike. The total cost received by the writing party (or parties) was $26.4K, with a price of $132.0 per contract. There were 34645 open contracts at this strike prior to today, and today 3195 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a call option sweep that happens to be bearish, expiring in 171 day(s) on January 17, 2025. This event was a transfer of 91 contract(s) at a $125.00 strike. This particular call needed to be split into 17 different trades to become filled. The total cost received by the writing party (or parties) was $35.0K, with a price of $385.0 per contract. There were 3887 open contracts at this strike prior to today, and today 1532 contract(s) were bought and sold. 
• For GEHC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>), we notice a put option sweep that happens to be bearish, expiring in 10 day(s) on August 9, 2024. This event was a transfer of 86 contract(s) at a $81.00 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $28.3K, with a price of $330.0 per contract. There were 47 open contracts at this strike prior to today, and today 748 contract(s) were bought and sold. 
• For BPMC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>), we notice a put option trade that happens to be bullish, expiring in 507 day(s) on December 19, 2025. This event was a transfer of 20 contract(s) at a $120.00 strike. The total cost received by the writing party (or parties) was $44.2K, with a price of $2210.0 per contract. There were 2354 open contracts at this strike prior to today, and today 227 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a put option trade that happens to be bullish, expiring in 52 day(s) on September 20, 2024. This event was a transfer of 100 contract(s) at a $48.00 strike. The total cost received by the writing party (or parties) was $29.5K, with a price of $295.0 per contract. There were 377 open contracts at this strike prior to today, and today 210 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a put option trade that happens to be bearish, expiring in 52 day(s) on September 20, 2024. This event was a transfer of 10 contract(s) at a $750.00 strike. The total cost received by the writing party (or parties) was $26.5K, with a price of $2650.0 per contract. There were 1011 open contracts at this strike prior to today, and today 182 contract(s) were bought and sold. 
• Regarding COR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), we observe a put option sweep with bullish sentiment. It expires in 17 day(s) on August 16, 2024. Parties traded 56 contract(s) at a $230.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $27.4K, with a price of $490.0 per contract. There were 176 open contracts at this strike prior to today, and today 158 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a call option trade with bullish sentiment. It expires in 143 day(s) on December 20, 2024. Parties traded 18 contract(s) at a $350.00 strike. The total cost received by the writing party (or parties) was $36.3K, with a price of $2020.0 per contract. There were 769 open contracts at this strike prior to today, and today 147 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMGN

GEHC

TEVA

VKTX

In the latest quarter, 15 analysts provided ratings for Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>), showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $116.47, a high estimate of $168.00, and a low estimate of $75.00. This upward trend is apparent, with the current average reflecting a 18.93% increase from the previous average price target of $97.93.
<img src="https://www.benzinga.com/files/images/story/2024/1722279652_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive Blueprint Medicines is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$105.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Michael Ulz</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$115.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Matthew Biegler</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$140.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Berens</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$97.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$168.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Sell</td>
<td>$76.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$104.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$97.00</td>
<td>$97.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Blueprint Medicines. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Blueprint Medicines compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Blueprint Medicines's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Blueprint Medicines's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BPMC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Blueprint Medicines analyst ratings.</a>
<h2>Unveiling the Story Behind Blueprint Medicines</h2>
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
<h3>Unraveling the Financial Story of Blueprint Medicines</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining Blueprint Medicines's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 51.87% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Blueprint Medicines's net margin excels beyond industry benchmarks, reaching 92.74%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Blueprint Medicines's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 40.4% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 8.54%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 1.06, Blueprint Medicines adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

15 Analysts Have This To Say About Blueprint Medicines

Barclays analyst Peter Lawson maintains Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Equal-Weight and raises the price target from $75 to $105.

Barclays Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $105

Morgan Stanley analyst Michael Ulz maintains Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Equal-Weight and raises the price target from $110 to $115.

Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $115

Oppenheimer analyst Matthew Biegler maintains Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Outperform and raises the price target from $114 to $125.

Oppenheimer Maintains Outperform on Blueprint Medicines, Raises Price Target to $125

During the last three months, 17 analysts shared their evaluations of Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>), revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Blueprint Medicines, presenting an average target of $116.35, a high estimate of $168.00, and a low estimate of $75.00. Witnessing a positive shift, the current average has risen by 14.52% from the previous average price target of $101.60.
<img src="https://www.benzinga.com/files/images/story/2024/1719579623_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Blueprint Medicines among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$140.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Berens</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$97.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$168.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Sell</td>
<td>$76.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$104.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$97.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$97.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Bradley Canino</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$114.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Blueprint Medicines. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Blueprint Medicines compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Blueprint Medicines's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Blueprint Medicines's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BPMC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Blueprint Medicines analyst ratings.</a>
<h2>All You Need to Know About Blueprint Medicines</h2>
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
<h3>A Deep Dive into Blueprint Medicines's Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Blueprint Medicines's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 51.87% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Blueprint Medicines's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 92.74%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Blueprint Medicines's ROE stands out, surpassing industry averages. With an impressive ROE of 40.4%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Blueprint Medicines's ROA excels beyond industry benchmarks, reaching 8.54%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.06.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings For Blueprint Medicines

In the preceding three months, 16 analysts have released ratings for Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $115.5, a high estimate of $168.00, and a low estimate of $75.00. Marking an increase of 19.69%, the current average surpasses the previous average price target of $96.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1717783275_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Blueprint Medicines is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$140.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Berens</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$97.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$168.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Sell</td>
<td>$76.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$104.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$97.00</td>
<td>-</td>
</tr>
<tr>
<td>Bradley Canino</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$125.00</td>
<td>-</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$97.00</td>
<td>-</td>
</tr>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$114.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Blueprint Medicines. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Blueprint Medicines compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Blueprint Medicines's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Blueprint Medicines's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BPMC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Blueprint Medicines analyst ratings.</a>
<h2>All You Need to Know About Blueprint Medicines</h2>
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
<h3>Blueprint Medicines: Delving into Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Blueprint Medicines displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 51.87%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Blueprint Medicines's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 92.74% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Blueprint Medicines's ROE excels beyond industry benchmarks, reaching 40.4%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Blueprint Medicines's ROA stands out, surpassing industry averages. With an impressive ROA of 8.54%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Blueprint Medicines's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.06.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Blueprint Medicines: Insights From 16 Financial Analysts

JMP Securities analyst Reni Benjamin reiterates Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Market Outperform and maintains $125 price target.

JMP Securities Reiterates Market Outperform on Blueprint Medicines, Maintains $125 Price Target

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/24/24</td>
<td>$133.00</td>
<td>$28.5K</td>
<td>477</td>
<td>2.1K</td>
</tr>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$45.00</td>
<td>$34.5K</td>
<td>20.0K</td>
<td>978</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$130.00</td>
<td>$121.4K</td>
<td>4.0K</td>
<td>389</td>
</tr>
<tr>
<td>IQV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$240.00</td>
<td>$32.3K</td>
<td>661</td>
<td>310</td>
</tr>
<tr>
<td>BPMC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$110.00</td>
<td>$47.8K</td>
<td>62</td>
<td>228</td>
</tr>
<tr>
<td>ARDX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$10.00</td>
<td>$28.3K</td>
<td>1.1K</td>
<td>174</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$95.00</td>
<td>$64.0K</td>
<td>1.2K</td>
<td>172</td>
</tr>
<tr>
<td>CYTK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/24/24</td>
<td>$60.00</td>
<td>$27.4K</td>
<td>19</td>
<td>135</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$100.00</td>
<td>$374.5K</td>
<td>1.7K</td>
<td>113</td>
</tr>
<tr>
<td>TDOC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/17/24</td>
<td>$12.00</td>
<td>$33.7K</td>
<td>922</td>
<td>110</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a call option sweep that happens to be bearish, expiring in 7 day(s) on May 24, 2024. This event was a transfer of 1018 contract(s) at a $133.00 strike. This particular call needed to be split into 54 different trades to become filled. The total cost received by the writing party (or parties) was $28.5K, with a price of $28.0 per contract. There were 477 open contracts at this strike prior to today, and today 2119 contract(s) were bought and sold. 
• For INSM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), we notice a call option sweep that happens to be bullish, expiring in 63 day(s) on July 19, 2024. This event was a transfer of 69 contract(s) at a $45.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $34.5K, with a price of $500.0 per contract. There were 20051 open contracts at this strike prior to today, and today 978 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a call option sweep with bearish sentiment. It expires in 35 day(s) on June 21, 2024. Parties traded 130 contract(s) at a $130.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $121.4K, with a price of $935.0 per contract. There were 4006 open contracts at this strike prior to today, and today 389 contract(s) were bought and sold. 
• Regarding IQV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>), we observe a call option sweep with bearish sentiment. It expires in 35 day(s) on June 21, 2024. Parties traded 100 contract(s) at a $240.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $32.3K, with a price of $323.0 per contract. There were 661 open contracts at this strike prior to today, and today 310 contract(s) were bought and sold. 
• Regarding BPMC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>), we observe a call option trade with bullish sentiment. It expires in 35 day(s) on June 21, 2024. Parties traded 114 contract(s) at a $110.00 strike. The total cost received by the writing party (or parties) was $47.8K, with a price of $420.0 per contract. There were 62 open contracts at this strike prior to today, and today 228 contract(s) were bought and sold. 
• Regarding ARDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>), we observe a put option sweep with bullish sentiment. It expires in 154 day(s) on October 18, 2024. Parties traded 107 contract(s) at a $10.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $28.3K, with a price of $265.0 per contract. There were 1133 open contracts at this strike prior to today, and today 174 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a call option sweep that happens to be bearish, expiring in 63 day(s) on July 19, 2024. This event was a transfer of 153 contract(s) at a $95.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $64.0K, with a price of $420.0 per contract. There were 1225 open contracts at this strike prior to today, and today 172 contract(s) were bought and sold. 
• Regarding CYTK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>), we observe a put option sweep with bearish sentiment. It expires in 7 day(s) on May 24, 2024. Parties traded 123 contract(s) at a $60.00 strike. This particular put needed to be split into 66 different trades to become filled. The total cost received by the writing party (or parties) was $27.4K, with a price of $220.0 per contract. There were 19 open contracts at this strike prior to today, and today 135 contract(s) were bought and sold. 
• For NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we notice a call option trade that happens to be bearish, expiring in 245 day(s) on January 17, 2025. This event was a transfer of 100 contract(s) at a $100.00 strike. The total cost received by the writing party (or parties) was $374.5K, with a price of $3745.0 per contract. There were 1745 open contracts at this strike prior to today, and today 113 contract(s) were bought and sold. 
• For TDOC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>), we notice a call option sweep that happens to be neutral, is expiring today. Parties traded 450 contract(s) at a $12.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $33.7K, with a price of $75.0 per contract. There were 922 open contracts at this strike prior to today, and today 110 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARDX

CYTK

INSM

TDOC

Ratings for Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) were provided by 18 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Blueprint Medicines, presenting an average target of $111.06, a high estimate of $168.00, and a low estimate of $65.00. Surpassing the previous average price target of $89.40, the current average has increased by 24.23%.
<img src="https://www.benzinga.com/files/images/story/2024/1715702435_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Blueprint Medicines by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$140.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Berens</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$97.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$168.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Sell</td>
<td>$76.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$104.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$97.00</td>
<td>-</td>
</tr>
<tr>
<td>Bradley Canino</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$125.00</td>
<td>-</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$97.00</td>
<td>-</td>
</tr>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$114.00</td>
<td>-</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$97.00</td>
<td>-</td>
</tr>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$114.00</td>
<td>-</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Sell</td>
<td>$65.00</td>
<td>$54.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Blueprint Medicines. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Blueprint Medicines compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Blueprint Medicines's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Blueprint Medicines's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BPMC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Blueprint Medicines analyst ratings.</a>
<h2>Unveiling the Story Behind Blueprint Medicines</h2>
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
<h3>A Deep Dive into Blueprint Medicines's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Blueprint Medicines's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 51.87%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Blueprint Medicines's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 92.74%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Blueprint Medicines's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 40.4% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Blueprint Medicines's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 8.54%, the company showcases efficient use of assets and strong financial health.
Debt Management: Blueprint Medicines's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.06.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 18 Analyst Insights On Blueprint Medicines

Goldman Sachs analyst Salveen Richter has maintained their bullish stance on BPMC stock, giving a Buy rating today. Salveen Richter's rating is bas...

Blueprint Medicines: A Strong Buy on Ayvakit's Success and Promising Pipeline

Blueprint Medicines Corporation (BPMC) Q2 2024 Earnings Call Transcript

In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Blueprint Medicines (BPMC – Research Report), with a price...

Blueprint Medicines: A Strong Buy on Impressive Financials and Promising Growth Trajectory

Analyst Andrew Fein of H.C. Wainwright reiterated a Buy rating on Blueprint Medicines (BPMC – Research Report), retaining the price target of $135....

Strong Sales and Market Potential Affirm Buy Rating for Blueprint Medicines

Barclays analyst Peter Lawson maintained a Hold rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $105.00. The...

Blueprint Medicines (BPMC) Receives a Hold from Barclays

TD Cowen analyst Marc Frahm maintained a Buy rating on Blueprint Medicines (BPMC – Research Report) today. The company's shares closed last Friday ...

TD Cowen Sticks to Their Buy Rating for Blueprint Medicines (BPMC)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Blueprint Medicines (BPMC – Research Report), Adaptimmune Therape...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Blueprint Medicines (BPMC), Adaptimmune Therapeutics (ADAP) and Ardelyx (ARDX)

Stocks with three weeks of deteriorating technicals by Piper Sandler

Blueprint Medicines: Growth For The Long Term Still Mostly Priced In

Cogent Biosciences: Need To Wait For More Data For Adequate Differentiation

ADAP

ARWR

COGT

CVBF

ENVX

HIMS

HOMB

INCY

LBRT

MITT

SIBN

SRCE

Press Releases

Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting

Legal

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Blueprint Medicines Corporation and Encourages Investors to Contact the Firm

Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)

Investors Have the Opportunity to Join the Following Securities Fraud Investigations: Avangrid, Inc. (AGR), Squarespace, Inc. (SQSP), and Blueprint Medicines Corporation (BPMC)

Comments

Blueprint Medicines

뉴스

에 대한 최신 뉴스 Blueprint Medicines (NASDAQ:BPMC) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌